Identified γ-glutamyl cyclotransferase (GGCT) as a novel regulator in the progression and immunotherapy of pancreatic ductal adenocarcinoma through multi-omics analysis and experiments.
Humans
Carcinoma, Pancreatic Ductal
/ pathology
Pancreatic Neoplasms
/ pathology
gamma-Glutamylcyclotransferase
/ metabolism
Immunotherapy
/ methods
Disease Progression
Cell Proliferation
Prognosis
Cell Line, Tumor
Biomarkers, Tumor
/ metabolism
Female
Gene Expression Regulation, Neoplastic
Male
Cell Movement
Multiomics
GGCT
Immunotherapy
Pan-cancer
Pancreatic ductal adenocarcinoma (PDAC)
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
25 Jun 2024
25 Jun 2024
Historique:
received:
20
03
2024
accepted:
07
05
2024
medline:
25
6
2024
pubmed:
25
6
2024
entrez:
24
6
2024
Statut:
epublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is renowned for its formidable and lethal nature, earning it a notorious reputation among malignant tumors. Due to its challenging early diagnosis, high malignancy, and resistance to chemotherapy drugs, the treatment of pancreatic cancer has long been exceedingly difficult in the realm of oncology. γ-Glutamyl cyclotransferase (GGCT), a vital enzyme in glutathione metabolism, has been implicated in the proliferation and progression of several tumor types, while the biological function of GGCT in pancreatic ductal adenocarcinoma remains unknown. The expression profile of GGCT was validated through western blotting, immunohistochemistry, and RT-qPCR in both pancreatic cancer tissue samples and cell lines. Functional enrichment analyses including GSVA, ssGSEA, GO, and KEGG were conducted to explore the biological role of GGCT. Additionally, CCK8, Edu, colony formation, migration, and invasion assays were employed to evaluate the impact of GGCT on the proliferation and migration abilities of pancreatic cancer cells. Furthermore, the LASSO machine learning algorithm was utilized to develop a prognostic model associated with GGCT. Our study revealed heightened expression of GGCT in pancreatic cancer tissues and cells, suggesting an association with poorer patient prognosis. Additionally, we explored the immunomodulatory effects of GGCT in both pan-cancer and pancreatic cancer contexts, found that GGCT may be associated with immunosuppressive regulation in various types of tumors. Specifically, in patients with high expression of GGCT in pancreatic cancer, there is a reduction in the infiltration of various immune cells, leading to poorer responsiveness to immunotherapy and worse survival rates. In vivo and in vitro assays indicate that downregulation of GGCT markedly suppresses the proliferation and metastasis of pancreatic cancer cells. Moreover, this inhibitory effect appears to be linked to the regulation of GGCT on c-Myc. A prognostic model was constructed based on genes derived from GGCT, demonstrating robust predictive ability for favorable survival prognosis and response to immunotherapy.
Sections du résumé
BACKGROUND
BACKGROUND
Pancreatic ductal adenocarcinoma (PDAC) is renowned for its formidable and lethal nature, earning it a notorious reputation among malignant tumors. Due to its challenging early diagnosis, high malignancy, and resistance to chemotherapy drugs, the treatment of pancreatic cancer has long been exceedingly difficult in the realm of oncology. γ-Glutamyl cyclotransferase (GGCT), a vital enzyme in glutathione metabolism, has been implicated in the proliferation and progression of several tumor types, while the biological function of GGCT in pancreatic ductal adenocarcinoma remains unknown.
METHODS
METHODS
The expression profile of GGCT was validated through western blotting, immunohistochemistry, and RT-qPCR in both pancreatic cancer tissue samples and cell lines. Functional enrichment analyses including GSVA, ssGSEA, GO, and KEGG were conducted to explore the biological role of GGCT. Additionally, CCK8, Edu, colony formation, migration, and invasion assays were employed to evaluate the impact of GGCT on the proliferation and migration abilities of pancreatic cancer cells. Furthermore, the LASSO machine learning algorithm was utilized to develop a prognostic model associated with GGCT.
RESULTS
RESULTS
Our study revealed heightened expression of GGCT in pancreatic cancer tissues and cells, suggesting an association with poorer patient prognosis. Additionally, we explored the immunomodulatory effects of GGCT in both pan-cancer and pancreatic cancer contexts, found that GGCT may be associated with immunosuppressive regulation in various types of tumors. Specifically, in patients with high expression of GGCT in pancreatic cancer, there is a reduction in the infiltration of various immune cells, leading to poorer responsiveness to immunotherapy and worse survival rates. In vivo and in vitro assays indicate that downregulation of GGCT markedly suppresses the proliferation and metastasis of pancreatic cancer cells. Moreover, this inhibitory effect appears to be linked to the regulation of GGCT on c-Myc. A prognostic model was constructed based on genes derived from GGCT, demonstrating robust predictive ability for favorable survival prognosis and response to immunotherapy.
Identifiants
pubmed: 38914714
doi: 10.1007/s00432-024-05789-0
pii: 10.1007/s00432-024-05789-0
doi:
Substances chimiques
gamma-Glutamylcyclotransferase
EC 4.3.2.9
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
318Subventions
Organisme : Qing Zhu
ID : ZYJC21042
Organisme : Qing Zhu
ID : ZYJC21042
Organisme : Qing Zhu
ID : ZYJC21042
Organisme : Qing Zhu
ID : ZYJC21042
Organisme : Qing Zhu
ID : ZYJC21042
Informations de copyright
© 2024. The Author(s).
Références
Ala M (2022) Target c-Myc to treat pancreatic cancer. Cancer Biol Ther 23:34–50. https://doi.org/10.1080/15384047.2021.2017223
doi: 10.1080/15384047.2021.2017223
pubmed: 34978469
pmcid: 8812741
Asano T, Yao Y, Zhu J, Li D, Abbruzzese JL, Reddy SAG (2004) The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23:8571–8580. https://doi.org/10.1038/sj.onc.1207902
doi: 10.1038/sj.onc.1207902
pubmed: 15467756
Azumi K, Ikeda Y, Takeuchi T, Nomura T, Sabau SV, Hamada J-I et al (2009) Localization and characterization of γ-glutamyl cyclotransferase in cancer cells. Mol Med Rep 2:385–391. https://doi.org/10.3892/mmr_00000110
doi: 10.3892/mmr_00000110
pubmed: 21475839
Bockorny B, Grossman JE, Hidalgo M (2022) Facts and hopes in immunotherapy of pancreatic cancer. Clin Cancer Res off J Am Assoc Cancer Res 28:4606–4617. https://doi.org/10.1158/1078-0432.CCR-21-3452
doi: 10.1158/1078-0432.CCR-21-3452
Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50:1–11. https://doi.org/10.1038/s12276-018-0191-1
doi: 10.1038/s12276-018-0191-1
pubmed: 30546008
Del Chiaro M, Sugawara T, Karam SD, Messersmith WA (2023) Advances in the management of pancreatic cancer. BMJ 383:e073995. https://doi.org/10.1136/bmj-2022-073995
doi: 10.1136/bmj-2022-073995
pubmed: 38164628
Emens LA, Middleton G (2015) The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res 3:436–443. https://doi.org/10.1158/2326-6066.CIR-15-0064
doi: 10.1158/2326-6066.CIR-15-0064
pubmed: 25941355
pmcid: 5012642
Fitzgerald AA, Wang S, Agarwal V, Marcisak EF, Zuo A, Jablonski SA et al (2021) DPP inhibition alters the CXCR3 axis and enhances NK and CD8+ T cell infiltration to improve anti-PD1 efficacy in murine models of pancreatic ductal adenocarcinoma. J Immunother Cancer 9:e002837. https://doi.org/10.1136/jitc-2021-002837
doi: 10.1136/jitc-2021-002837
pubmed: 34737215
pmcid: 8578994
Gromov P, Gromova I, Friis E, Timmermans-Wielenga V, Rank F, Simon R et al (2010) Proteomic profiling of mammary carcinomas identifies C7orf24, a γ-glutamyl cyclotransferase, as a potential cancer biomarker. J Proteome Res 9:3941–3953. https://doi.org/10.1021/pr100160u
doi: 10.1021/pr100160u
pubmed: 20527979
Guo Q, Xiao X, Lu L, Ai L, Xu M, Liu Y et al (2022) Polyphenol-polysaccharide complex: preparation, characterization, and potential utilization in food and health. Annu Rev Food Sci Technol 13:59–87. https://doi.org/10.1146/annurev-food-052720-010354
doi: 10.1146/annurev-food-052720-010354
pubmed: 35041793
Halbrook CJ, Lyssiotis CA, Pasca di Magliano M, Maitra A (2023) Pancreatic cancer: advances and challenges. Cell 186:1729–1754. https://doi.org/10.1016/j.cell.2023.02.014
doi: 10.1016/j.cell.2023.02.014
pubmed: 37059070
pmcid: 10182830
Hatem E, El Banna N, Huang M-E (2017) Multifaceted roles of glutathione and glutathione-based systems in carcinogenesis and anticancer drug resistance. Antioxid Redox Signal 27:1217–1234. https://doi.org/10.1089/ars.2017.7134
doi: 10.1089/ars.2017.7134
pubmed: 28537430
He Z, Wang S, Shao Y, Zhang J, Wu X, Chen Y et al (2019) Ras downstream effector GGCT alleviates oncogenic stress. iScience. 19:256–266. https://doi.org/10.1016/j.isci.2019.07.036
doi: 10.1016/j.isci.2019.07.036
pubmed: 31400748
pmcid: 6700472
He S, Xia C, Li H, Cao M, Yang F, Yan X et al (2024) Cancer profiles in China and comparisons with the USA: a comprehensive analysis in the incidence, mortality, survival, staging, and attribution to risk factors. Sci China Life Sci 67:122–131. https://doi.org/10.1007/s11427-023-2423-1
doi: 10.1007/s11427-023-2423-1
pubmed: 37755589
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X et al (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med 24:1550–1558. https://doi.org/10.1038/s41591-018-0136-1
doi: 10.1038/s41591-018-0136-1
pubmed: 30127393
pmcid: 6487502
Ju W, Zheng R, Zhang S, Zeng H, Sun K, Wang S et al (2023) Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea. Sci China Life Sci 66:1079–1091. https://doi.org/10.1007/s11427-022-2218-x
doi: 10.1007/s11427-022-2218-x
pubmed: 36543994
Kageyama S, Ii H, Taniguchi K, Kubota S, Yoshida T, Isono T et al (2018) Mechanisms of tumor growth inhibition by depletion of γ-glutamylcyclotransferase (GGCT): a novel molecular target for anticancer therapy. Int J Mol Sci 19:2054. https://doi.org/10.3390/ijms19072054
doi: 10.3390/ijms19072054
pubmed: 30011933
pmcid: 6073726
Li Y, Wu T, Wang Y, Yang L, Hu C, Chen L et al (2018) γ-glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway. Gynecol Oncol 149:163–172. https://doi.org/10.1016/j.ygyno.2018.01.023
doi: 10.1016/j.ygyno.2018.01.023
pubmed: 29429592
Li H-N, Zhang H-M, Li X-R, Wang J, Xu T, Li S-Y et al (2022) MiR-205–5p/GGCT attenuates growth and metastasis of papillary thyroid cancer by regulating CD44. Endocrinology 163:bqac022
doi: 10.1210/endocr/bqac022
pubmed: 35213720
pmcid: 8944316
Liu Y, Hyde AS, Simpson MA, Barycki JJ (2014) Emerging regulatory paradigms in glutathione metabolism. Adv Cancer Res 122:69–101. https://doi.org/10.1016/B978-0-12-420117-0.00002-5
doi: 10.1016/B978-0-12-420117-0.00002-5
pubmed: 24974179
pmcid: 4515967
Liu S, Galat V, Galat Y, Lee YKA, Wainwright D, Wu J (2021) NK cell-based cancer immunotherapy: from basic biology to clinical development. J Hematol OncolJ Hematol Oncol 14:7. https://doi.org/10.1186/s13045-020-01014-w
doi: 10.1186/s13045-020-01014-w
Liu Z, Liu L, Weng S, Xu H, Xing Z, Ren Y et al (2023) BEST: a web application for comprehensive biomarker exploration on large-scale data in solid tumors. J Big Data 10:165. https://doi.org/10.1186/s40537-023-00844-y
doi: 10.1186/s40537-023-00844-y
Llombart V, Mansour MR (2022) Therapeutic targeting of “undruggable” MYC. EBioMedicine 75:103756. https://doi.org/10.1016/j.ebiom.2021.103756
doi: 10.1016/j.ebiom.2021.103756
pubmed: 34942444
National Cancer Institute (2020) Surveillance, epidemiology, and end results Program. Qeios, New York
doi: 10.32388/5OWTL5
Niu B, Liao K, Zhou Y, Wen T, Quan G, Pan X et al (2021) Application of glutathione depletion in cancer therapy: enhanced ROS-based therapy, ferroptosis, and chemotherapy. Biomaterials 277:121110. https://doi.org/10.1016/j.biomaterials.2021.121110
doi: 10.1016/j.biomaterials.2021.121110
pubmed: 34482088
Oakley AJ, Yamada T, Liu D, Coggan M, Clark AG, Board PG (2008) The identification and structural characterization of C7orf24 as gamma-glutamyl cyclotransferase. An essential enzyme in the gamma-glutamyl cycle. J Biol Chem 283:22031–22042. https://doi.org/10.1074/jbc.M803623200
doi: 10.1074/jbc.M803623200
pubmed: 18515354
O’Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W et al (2019) Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol 5:1431–1438. https://doi.org/10.1001/jamaoncol.2019.1588
doi: 10.1001/jamaoncol.2019.1588
pubmed: 31318392
pmcid: 6647002
Principe DR, Korc M, Kamath SD, Munshi HG, Rana A (2021) Trials and tribulations of pancreatic cancer immunotherapy. Cancer Lett 504:1–14. https://doi.org/10.1016/j.canlet.2021.01.031
doi: 10.1016/j.canlet.2021.01.031
pubmed: 33549709
pmcid: 7940598
Schubert M, Klinger B, Klünemann M, Sieber A, Uhlitz F, Sauer S et al (2018) Perturbation-response genes reveal signaling footprints in cancer gene expression. Nat Commun 9:20. https://doi.org/10.1038/s41467-017-02391-6
doi: 10.1038/s41467-017-02391-6
pubmed: 29295995
pmcid: 5750219
Sharma N, Nanta R, Sharma J, Gunewardena S, Singh KP, Shankar S et al (2015) PI3K/AKT/mTOR and sonic hedgehog pathways cooperate together to inhibit human pancreatic cancer stem cell characteristics and tumor growth. Oncotarget 6:32039–32060. https://doi.org/10.18632/oncotarget.5055
doi: 10.18632/oncotarget.5055
pubmed: 26451606
pmcid: 4741658
Shen S-H, Yu N, Liu X-Y, Tan G-W, Wang Z-X (2016) Gamma-glutamylcyclotransferase promotes the growth of human glioma cells by activating Notch-Akt signaling. Biochem Biophys Res Commun 471:616–620. https://doi.org/10.1016/j.bbrc.2016.01.165
doi: 10.1016/j.bbrc.2016.01.165
pubmed: 26828272
Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17–48. https://doi.org/10.3322/caac.21763
doi: 10.3322/caac.21763
pubmed: 36633525
Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD (2019) ROS and the DNA damage response in cancer. Redox Biol 25:101084. https://doi.org/10.1016/j.redox.2018.101084
doi: 10.1016/j.redox.2018.101084
pubmed: 30612957
Takemura K, Kawachi H, Eishi Y, Kitagaki K, Negi M, Kobayashi M, Uchida K, Inoue J, Inazawa J, Kawano T, Board PG et al (2014) γ-Glutamylcyclotransferase as a novel immunohistochemical biomarker for the malignancy of esophageal squamous tumors. Hum Pathol 45:331–341. https://doi.org/10.1016/j.humpath.2013.09.009
doi: 10.1016/j.humpath.2013.09.009
pubmed: 24342434
Taniguchi K, Matsumura K, Ii H, Kageyama S, Ashihara E, Chano T et al (2018) Depletion of gamma-glutamylcyclotransferase in cancer cells induces autophagy followed by cellular senescence. Am J Cancer Res 8:650–661
pubmed: 29736310
pmcid: 5934555
Taniguchi K, Kageyama S, Moyama C, Ando S, Ii H, Ashihara E et al (2022) γ-glutamylcyclotransferase, a novel regulator of HIF-1α expression, triggers aerobic glycolysis. Cancer Gene Ther 29:37–48. https://doi.org/10.1038/s41417-020-00287-0
doi: 10.1038/s41417-020-00287-0
pubmed: 33402732
Weng N, Qin S, Liu J, Huang X, Jiang J, Zhou L et al (2022) Repurposing econazole as a pharmacological autophagy inhibitor to treat pancreatic ductal adenocarcinoma. Acta Pharm Sin b 12:3085–3102. https://doi.org/10.1016/j.apsb.2022.01.018
doi: 10.1016/j.apsb.2022.01.018
pubmed: 35865101
pmcid: 9293665
Xu S, Yang Y, Wang X, Liu X, Jin C, Ma M, Wu S, Li Y et al (2020) γ-Glutamyl cyclotransferase contributes to endometrial carcinoma malignant progression and upregulation of PD-L1 expression during activation of epithelial-mesenchymal transition. Int Immunopharmacol 81:106039. https://doi.org/10.1016/j.intimp.2019.106039
doi: 10.1016/j.intimp.2019.106039
pubmed: 31757677
Zhang C, Li H-R, Fan J-B, Wang-Rodriguez J, Downs T, Fu X-D et al (2006) Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics 7:202. https://doi.org/10.1186/1471-2105-7-202
doi: 10.1186/1471-2105-7-202
pubmed: 16608523
pmcid: 1458362
Zhang W, Chen L, Xiang H, Hu C, Shi W, Dong P et al (2016) Knockdown of GGCT inhibits cell proliferation and induces late apoptosis in human gastric cancer. BMC Biochem 17:19. https://doi.org/10.1186/s12858-016-0075-8
doi: 10.1186/s12858-016-0075-8
pubmed: 27905872
pmcid: 5134233
Zhang H-M, Li Z-Y, Dai Z-T, Wang J, Li L-W, Zong Q-B et al (2022) Interaction of MRPL9 and ggct promotes cell proliferation and migration by activating the MAPK/ERK pathway in papillary thyroid cancer. Int J Mol Sci 23:11989. https://doi.org/10.3390/ijms231911989
doi: 10.3390/ijms231911989
pubmed: 36233293
pmcid: 9570013
Zheng H, Liu H, Ge Y, Wang X (2021) Integrated single-cell and bulk RNA sequencing analysis identifies a cancer associated fibroblast-related signature for predicting prognosis and therapeutic responses in colorectal cancer. Cancer Cell Int 21:552. https://doi.org/10.1186/s12935-021-02252-9
doi: 10.1186/s12935-021-02252-9
pubmed: 34670584
pmcid: 8529760